---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-134097"
form_type: "8-K/A"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2026-03-31T23:59:59+00:00"
generated_at: "2026-05-15T08:10:08.000043+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LeonaBio files amended 8-K on Sermonix license, provides ELAINE-3 cost and timeline update

## Summary
- SEC granted waiver from providing Sermonix financial statements; license deal treated as business acquisition under Regulation S-X.
- Sermonix reported ELAINE-3 cash expenditures of $14M (2023), $12M (2024), $5M (2025 through Dec 18).
- LeonaBio expects $45M (2026) and $30M (2027) in ELAINE-3 cash spend; made ~$11M from Dec 18–31, 2025.
- ELAINE-3 protocol amended to increase sample size from 500 to up to 600; enrollment completion targeted Q4 2026, topline data H2 2027.
- License agreement grants LeonaBio exclusive rights to lasofoxifene for oncology outside Retained Territory.

## SEC filing metadata
- accession: 0001193125-26-134097
- form_type: 8-K/A
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2026-03-31T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 9.01, 2.01, 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/0001193125-26-134097-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000119312526134097/lona-20251218.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-134097
- JSON: https://secwatch.observer/filing/0001193125-26-134097.json
- Plain text: https://secwatch.observer/filing/0001193125-26-134097.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.